# Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

> **NCT00838656** · PHASE2 · UNKNOWN · sponsor: **Warwick Medical School** · enrollment: 88 (estimated)

## Conditions studied

- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer

## Interventions

- **DRUG:** carboplatin
- **DRUG:** gemcitabine hydrochloride
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT00838656
- **Lead sponsor:** Warwick Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-10
- **Primary completion:** 2009-06
- **Final completion:** —
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2013-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00838656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00838656, "Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00838656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*